As the cold season approaches, many turn to familiar antiviral medications like Arbidol, Kagocel, Ingavirin, and Cycloferon, but recent evaluations indicate that their effectiveness may not be as robust as many believe. A review of these medications against the backdrop of global health recommendations reveals a complex picture. While they are widely available in Russian pharmacies, none of these seven treatments can be confidently classified alongside antiviral drugs that have a strong international evidence base.
Current health guidelines from the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) suggest that while some antivirals may be beneficial for treating severe influenza, the routine use of many of these medications for mild cases is discouraged. Specifically, the WHO recommends oseltamivir for severe influenza cases, while for mild cases in low-risk patients, the use of antivirals like oseltamivir and umifenovir is not endorsed.
Arbidol, containing umifenovir, presents a particularly complicated case. While it has undergone randomized controlled trials, the WHO's 2024 evaluation found only a modest reduction in symptom duration, leading to a conditional recommendation against its use for mild influenza. Russian clinical guidelines, however, still support its use with varying levels of confidence.
Kagocel, another registered antiviral in Russia, lacks substantial high-quality evidence to support its efficacy. Most studies available are dated or observational, which do not meet the rigorous standards set by major health organizations. Similarly, Ingavirin has had its effectiveness questioned due to a lack of recent, large-scale, independent studies confirming its benefits.
Furthermore, the evidence for Cycloferon is limited, with older studies failing to meet modern research standards. The presence of registration in Russia does not equate to proven efficacy, as seen with these medications.
The findings highlight a critical gap between the availability of these antivirals and their proven effectiveness in clinical practice. As these medications remain popular choices for treating influenza and ARVI, their uncertain efficacy may prompt consumers to reconsider their options. This situation presents a significant opportunity for competing antiviral treatments that offer stronger evidence and clearer guidelines, potentially reshaping the market landscape.
Informational material. 18+.
